Ursofalk Drug Interactions

Ursofalk capsules should not be administered concomitantly with colestyramine, colestipol or antacids containing aluminium hydroxide and/or smectite (aluminium oxide), because these preparations bind ursodeoxycholic acid in the intestine and thereby reduce its absorption and efficacy. Should the use of a preparation containing one of these substances be necessary, it must be taken at least 2 hours before or after Ursofalk capsules.
Ursofalk capsules can increase the absorption of ciclosporin from the intestine. In patients receiving ciclosporin treatment, blood concentrations of this substance should therefore be checked by the physician and the ciclosporin dose adjusted if necessary.
In isolated cases, Ursofalk capsules can reduce the absorption of ciprofloxacin.
Ursodeoxycholic acid reduces peak plasma concentrations (C_max) and area under the curve (AUC) of the calcium antagonist nitrendipine. On the basis of this, together with a single case report of an interaction with the substance dapsone (reduction of the therapeutic effect) and in-vitro findings, it may be assumed that ursodeoxycholic acid induces the drug-metabolising enzyme cytochrome P450 3A4.Caution should therefore be exercised in cases of co-administration of drugs metabolised via this enzyme, and a dose adjustment may be necessary.